A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Postnatal depression
  • Focus Therapeutic Use
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 02 Nov 2017 According to a Sage Therapeutics media release, company expects to report top-line results in 1Q 2018.
    • 02 Nov 2017 According to a Sage Therapeutics media release, company expects to complete enrollment in 4Q 2017.
    • 31 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top